4th International Summit on Lung Cancer Highlights by Stephen V Liu

The 4th International Summit on Lung Cancer was held on May 10–11, 2025, at Hotel Villa Pamphili in Rome, Italy. This in-person, residential event brought together leading experts in thoracic oncology to discuss cutting-edge developments in lung cancer research, diagnosis, and treatment.

Chaired by renowned oncologists including Federico Cappuzzo, Lorenza Landi, and Tina Cascone, the summit featured sessions on early detection, biomarkers, neoadjuvant therapies, and innovative approaches to managing metastatic disease. Special focus was given to the integration of immunotherapy and targeted therapies into clinical practice.

Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared some insights from 4th International Summit on Lung Cancer:

Eve of RomeLung25

“Eve of RomeLung25 – catching up with friends from all over, ready to discuss, debate, learn from each other and work out new strategies for lung cancer.”

Opening RomeLung25 with Federico Cappuzzo and Lorenza Landi

“Opening RomeLung25 with chairs Federico Cappuzzo and Lorenza Landi – the 4th annual International Summit on Lung Cancer.”

Dr. Anne-Marie Dingemans on T cell engagers in SCLC

“Dr. Anne-Marie Dingemans at RomeLung25 presents a summary of T cell engagers in SCLC including tarlatamab, obrixtamig, MK-6070 – highlighting unanswered questions: ideal setting? CNS efficacy? How to improve access, decrease need for hospitalization? Biomarkers?”

What’s Next for SCLC? Dr. Alessandra Curioni Notes Therapeutic Potential

“What’s next for SCLC? Dr. Alessandra Curioni notes potential of various classes including radiopharmaceuticals, targeted agents, epigenetic therapy, and cell therapy. Stay tuned.”

Dr. Jia Wu on AI innovations in lung cancer

“Dr. Jia Wu at RomeLung25 discusses AI innovations in lung cancer. Can we better assess response, likelihood of response, risk of progression/tox, risk of cancer? Processing terabytes of data for each patient will significantly improve precision in the very near future.”

Dr. Noemi Reguart discusses PD1/VEGF bispecifics in NSCLC

“Dr. Noemi Reguart discusses PD1/VEGF bispecifics in NSCLC at RomeLung25. Many compounds in development- ivonescimab and BNT-327 furthest along. Encouraging results from HARMONi-2. Will cooperative binding and complex formation lead to better survival? Need to see full results here.”

Dr. Yilong Wu on the potential of PD1/VEGF bispecifics in driver positive NSCLC

“Dr. Yilong Wu shows the potential of PD1/VEGF bispecifics in driver positive NSCLC at RomeLung25. HARMONi-A showed the PFS benefit of ivonescimab in EGFR NSCLC. BNT-327 showed much greater benefit with higher PDL1 expression. Will this impact survival?”

Dr. Enriqueta Felip discusses MET as an ADC target

“Dr. Enriqueta Felip discusses MET as an ADC target at RomeLung25. Expecting to see telisotuzumab vedotin as an option soon for cMET overexpressing NSCLC – and awaiting data from randomized trial vs docetaxel. Some new agents in this space as well.”

Dr. Jessica J Lin at RomeLung25 updates treatment for ALK NSCLC

“Dr. Jessica J Lin at RomeLung25 updates treatment for ALK NSCLC. Many TKIs approved, PFS greatest for lorlatinib but NVL-655 (neladalkib) emerging as an active agent in later lines and will be compared to alectinib in 1L in phase 3 trial.”

Overview of ROS1 in NSCLC by Dr. Fabrice Barlesi

“Overview of ROS1 in NSCLC by Dr. Fabrice Barlesi at RomeLung25? Three approved drugs – crizotinib, entrectinib, most recently, repotrectinib – all very active agents. At progression, lorlatinib may be an option at progression but chemotherapy is active with emerging agents like NVL -510.”

Dr. Ferdinandos Skoulidis at RomeLung25 with updates on KRAS inhibition

“Dr. Ferdinandos Skoulidis at RomeLung25 with updates on KRAS inhibition. Two approved KRAS G12C inhibitors, sotorasib and adagrasib, with next generation inhibitors divarasib and D3S-001 emerging as next generation agents with robust efficacy.”

More posts about NSCLC.

Non-Small Cell Lung Cancer: Causes, Symptoms, Diagnosis, Treatment Options, and Latest 2025 Advances in Targeted and Immunotherapy